Daniel Lim

IP lawyer at Kirkland & Ellis, specialising in life sciences patent litigation. I am particularly interested in CRISPR, I-O and molecular Dx. Views my own.

[Daniel Lim @Daniel_CY_Lim]

Thrilled to be joining @Kirkland_Ellis to help build our new #IP litigation practice in London alongside the most talented friends and colleagues I know, @DaggNicola, Katie Coltart, Jin Ooi and Steven Baldwin!

Please reach out if you'd like to know more!

https://t.co/2G4qh8W2a4

[Daniel Lim @Daniel_CY_Lim]

Great to speak to @benwodecki of @ipmagazine about such an important topic in the current circumstances. #IP in life sciences and pharma has always divided opinion but #COVID19 has shone an even brighter spotlight on it than ever before. As ever, striking the right balance is key

[Kirkland & Ellis @Kirkland_Ellis]

Partner @Daniel_CY_Lim discusses the #COVID19 pandemic's impact on the life sciences industry. [Article available to subscribers] https://t.co/mDE5notVSM

[Daniel Lim @Daniel_CY_Lim]

Was a wonderful opportunity to share views from government, industry and originate practice, and to rightly reassure the global IP community that the UK will continues to be a leading place to innovate and protect IP!

[Daniel Lim @Daniel_CY_Lim]

I was privileged to moderate the #AIPPI2019 panel session on #Brexit and #IP, joined by a fantastic diverse panel: Adam Williams, Ewan Nettleton, Bin Sun, Joost van Ooijen and Aurélia Marie

Thanks to all who attended and the panel for joining me to deal with such a tricky topic!

[Daniel Lim @Daniel_CY_Lim]

The key takeaway the panel wanted to convey was that there will be certainty and continuity as regards the major IP rights upon Brexit, irrespective of any political uncertainty.

[Daniel Lim @Daniel_CY_Lim]

From an IP office POV there are 2 key questions when it comes to #AI and patents: (1) what law/policy needs to be in place to encourage and promulgate #AI development; (2) how should the Office incorporate AI into its processes - AI is not a nice to have but will be a *must have*

[Daniel Lim @Daniel_CY_Lim]

@uspto Director Andrei Iancu speaking to attendees at #AIPPI2019. Getting straight to the point - section 101 patent eligibility right off the bat!

Director Iancu observing that the guidelines in the USPTO are working well but courts are independent and don’t necessarily follow

[Daniel Lim @Daniel_CY_Lim]

Director Iancu emphasising that the point of section 101 is to keep out subject matter that should never be able to be patented, irrespective of the form of the claim. The creep of concepts of vagueness or inventive step into a 101 analyses runs against this...

[Daniel Lim @Daniel_CY_Lim]

@uspto Director Andrei Iancu speaking to attendees at #AIPPI2019. Getting straight to the point - section 101 patent eligibility right off the bat!

Director Iancu observing that the guidelines in the USPTO are working well but courts are independent and don’t necessarily follow

[Daniel Lim @Daniel_CY_Lim]

A very bright and sunny London is pulling out all the stops for the start of #AIPPI2019! Looking forward to catching up with friends across the IP world over the next few days. Hoping for a big turnout at Tuesday’s panel on #Brexit and #IP, moderated by yours truly! @AIPPI_ORG

[Daniel Lim @Daniel_CY_Lim]

@mitchellrayoco1 @NIH @NIGMS Awesome @mitchellrayoco1 !!!

[Daniel Lim @Daniel_CY_Lim]

Final takeaways from #CRISPRcon2019 for the audience. Another great conference, filled with really engaging discussions. Well done to all the organisers and attendees for making it such an excellent forum

[Daniel Lim @Daniel_CY_Lim]

Excited to be in beautiful Wagenigen @WUR for #CRISPRCON2019! Looking forward to great conversations with a diverse audience from a variety of industry sectors and backgrounds over the next two days. @CRISPRcon

[Daniel Lim @Daniel_CY_Lim]

Guobin with a lovely parting sentiment - the world needs to find an effective way for people to understand each other